Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Lesalpes29on Aug 06, 2022 8:30am
181 Views
Post# 34876124

RE:RE:RE:RE:RE:RE:RE:RE:Deals are abound!!!!

RE:RE:RE:RE:RE:RE:RE:RE:Deals are abound!!!!
Buckhenry wrote:
The thing here is Matt has poured his life into this and I dont think he is going to sell at this time. if the revenue projections are correct they would see close to 5B in 2025. if that is even close I would not sell the company for anything less than 50B if I were him. the one issue is.... can he hold out until he gets that revenue stream. the stock price would obviously go up dramatically if that were to occur. I think matt wants to be another Pfizer... not sell to Pfizer. thoughts??

Don’t know but if the product prove to be effective in all studies that are going on, how can we prevent a cheap buyout. Of course, if results continue to be good the SP will follow and will be in a better shape. I’m concern about an hostile and cheap buyout.
<< Previous
Bullboard Posts
Next >>